In patients with heart failure with reduced ejection fraction, how do finerenone and eplerenone compare regarding first‑line use, dosing, and monitoring?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Finerenone vs Eplerenone for HFrEF

For patients with HFrEF, eplerenone remains the established first-line mineralocorticoid receptor antagonist (MRA) with proven mortality benefit, while finerenone is not currently indicated for HFrEF and should not be used in this population. 1

FDA-Approved Indications

Eplerenone for HFrEF

  • FDA-approved indication: Eplerenone is specifically indicated to improve survival in stable patients with symptomatic HFrEF (LVEF ≤40%) after acute myocardial infarction 1
  • This approval is based on robust mortality data from the EPHESUS trial demonstrating significant reductions in cardiovascular mortality and hospitalization 2, 3

Finerenone Exclusion in HFrEF

  • Critical exclusion: Patients with heart failure with reduced ejection fraction were explicitly excluded from the FIDELIO-DKD and FIGARO-DKD trials that established finerenone's evidence base 4, 5
  • Finerenone has no FDA approval for HFrEF and lacks outcome data in this population 6, 4

Guideline Recommendations for HFrEF

Current guidelines uniformly recommend steroidal MRAs (spironolactone or eplerenone) as foundational therapy for HFrEF: 7, 2, 8

  • The 2025 Canadian guidelines list both spironolactone and eplerenone as evidence-based MRA options for HFrEF, but notably do not include finerenone for this indication 7
  • The 2022 AHA/ACC/HFSA guidelines establish MRAs as one of four foundational medication classes for HFrEF (along with SGLT2 inhibitors, ACE inhibitors/ARBs/ARNIs, and beta-blockers) 8
  • The 2021 Canadian guidelines give a Strong Recommendation with High-Quality Evidence for MRA treatment in HFrEF, specifically naming spironolactone and eplerenone 2

Dosing Protocols

Eplerenone Dosing for HFrEF

Starting dose: 25 mg once daily 1

  • Target dose: 50 mg once daily, preferably achieved within 4 weeks as tolerated 1
  • Dose adjustments based on potassium levels: 1
    • Potassium <5.0 mEq/L: Increase from 25 mg every other day to 25 mg daily, or from 25 mg daily to 50 mg daily
    • Potassium 5.0-5.4 mEq/L: No adjustment needed
    • Potassium 5.5-5.9 mEq/L: Decrease dose (50 mg daily to 25 mg daily, or 25 mg daily to every other day)
    • Potassium ≥6.0 mEq/L: Withhold and restart at 25 mg every other day when potassium <5.5 mEq/L

Finerenone Dosing (Not for HFrEF)

  • Finerenone dosing (10-40 mg daily) has only been established for diabetic kidney disease, not HFrEF 7, 5

Monitoring Requirements

For Eplerenone in HFrEF

  • Renal function threshold: MRAs should generally be avoided when eGFR <30 mL/min/1.73 m² 2
  • Potassium and creatinine monitoring: Repeat within 1 week of initiation or dose change 2
  • Temporary interruption criteria: 2
    • Moderate hyperkalemia (5.6-5.9 mmol/L): Consider dose reduction
    • Severe hyperkalemia (>5.9 mmol/L): Withhold until potassium ≤5.0 mmol/L

Clinical Trial Evidence Comparison

Eplerenone Evidence in HFrEF

  • EPHESUS trial: Demonstrated significant mortality reduction in post-MI HFrEF patients 2, 3
  • EMPHASIS-HF trial: Showed benefit in mild symptoms (NYHA class II) HFrEF 3
  • Both trials excluded patients with potassium >5 mmol/L and severe renal impairment (creatinine >2.5 mg/dL) 3

Finerenone Evidence (Not in HFrEF)

  • ARTS-HF trial: This was a phase 2b study comparing finerenone to eplerenone in worsening HF patients, but it was designed for NT-proBNP reduction, not mortality outcomes 9
  • The trial showed similar NT-proBNP reductions but was underpowered for clinical events 9
  • Important limitation: Finerenone's cardiovascular benefits demonstrated in FIDELIO-DKD and FIGARO-DKD specifically excluded HFrEF patients 4, 5

Safety Profile Considerations

Hyperkalemia Risk

  • Eplerenone: Well-established safety profile in HFrEF with protocol-driven monitoring 2, 1
  • Finerenone: While meta-analyses suggest potentially lower hyperkalemia rates compared to steroidal MRAs in other populations 10, 11, this has not been validated in HFrEF patients

Renal Function

  • Both agents require caution with reduced eGFR, but eplerenone has established dosing protocols for HFrEF 2, 1
  • Finerenone showed better eGFR preservation in diabetic kidney disease trials, but these excluded HFrEF 4

Common Pitfalls to Avoid

  1. Do not use finerenone for HFrEF: It lacks FDA approval, guideline support, and outcome data in this population 6, 4, 5
  2. Do not delay MRA initiation: MRAs should be started early as foundational therapy alongside SGLT2 inhibitors, RAS inhibitors, and beta-blockers 2, 8
  3. Do not withhold due to mild hyperkalemia: Temporary dose adjustments are preferred over permanent discontinuation when potassium is 5.5-5.9 mmol/L 2
  4. Do not confuse indications: Finerenone's role is in diabetic kidney disease and HFmrEF/HFpEF, not HFrEF 6, 7, 5

Where Finerenone Does Have a Role

Finerenone is appropriate for: 6, 7, 5

  • Diabetic kidney disease (primary indication)
  • Heart failure with mildly reduced (LVEF 41-49%) or preserved ejection fraction (LVEF ≥50%)
  • Prevention of progression from stage A heart failure to symptomatic heart failure in diabetic kidney disease patients

References

Related Questions

Can finerenone (Kerendia) be used instead of spironolactone in patients with heart failure with reduced ejection fraction who develop hyperkalemia?
What is a newer alternative diuretic to Spironolactone (spironolactone) and Eplerenone (eplerenone) for heart failure that does not cause gynecomastia?
Can finerenone and spironolactone be used together in the same patient?
What are the recommended dosing, monitoring parameters, contraindications, and adverse effects of fenerenone for treating hypertension and chronic heart failure?
In a patient with heart failure with preserved ejection fraction, serum potassium 4.8 mEq/L and estimated glomerular filtration rate approximately 52 mL/min, should finerenone be initiated instead of spironolactone, and what dosing and monitoring plan is recommended?
In a patient with an active hematoma and deep vein thrombosis, should they be admitted and how should anticoagulant therapy be managed?
What are the appropriate intramuscular injection sites for hepatitis A immunoglobulin and hepatitis B immunoglobulin in adults and children based on injection volume?
How does the cerebrospinal fluid meningitis panel compare to the QIAstat-Dx Meningitis/Encephalitis multiplex PCR test?
In upper extremity compartment syndrome, where does bleeding typically occur?
What is the appropriate duration of antibiotic therapy for group B Streptococcus bacteremia?
Is Streptococcus agalactiae the same as Group B Streptococcus?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.